Swiss Stock News

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Novartis (SWX:NOVN) received a positive CHMP opinion for remibrutinib, an oral BTK inhibitor for chronic spontaneous urticaria. The opinion is based on Phase III data in patients who do not respond adequately to antihistamines. The company also announced a new radioligand therapy manufacturing facility in Texas, expanding its US production footprint. For investors, these twin updates put both immunology and radioligand therapies in focus for Novartis at a time when the share price stands at...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

Kuehne + Nagel International (SWX:KNIN) reported a substantial decline in recurring operating earnings. Full year results show lower recurring earnings before interest and tax compared with the prior year. Net income for the same period also moved lower, pointing to pressure on overall profitability. The figures highlight ongoing challenges across the transport and logistics sector. Kuehne + Nagel is a major global player in sea, air, and contract logistics, so its results often provide a...

Why Emmi’s latest earnings matter for shareholders Emmi (SWX:EMMN) has just reported its full year 2025 results, with revenue of CHF 4,745.69 million and net income of CHF 227.06 million, putting fresh fundamentals in focus for anyone tracking the stock. See our latest analysis for Emmi. Emmi’s 12.0% 90 day share price return and 13.57% year to date share price return suggest momentum has picked up ahead of these results, even though the 1 year total shareholder return is slightly...

UBS Group (SWX:UBSG) has nominated Agustín Carstens and Luca Maestri to join its Board of Directors. The nominations come alongside the planned retirement of several long-serving board members. The board changes are tied to UBS’s ongoing integration of Credit Suisse and evolving regulatory expectations. UBS Group, a global wealth manager and investment bank, is in the middle of absorbing Credit Suisse while operating under tighter regulatory scrutiny. Bringing in leaders with regulatory,...

Forbo Holding (SWX:FORN) has released its FY 2025 first half results with revenue of CHF 546.9 million and basic EPS of CHF 23.70, while trailing 12 month figures show revenue of CHF 1.10 billion and EPS of CHF 56.78. Over the last few reporting halves, revenue has moved from CHF 570.3 million and EPS of CHF 34.36 in 1H 2024 to CHF 551.7 million and EPS of CHF 33.07 in 2H 2024, before landing at the latest 1H 2025 levels. The trailing 12 month net profit margin now sits at 7.3% versus 8.3% a...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

ARYZTA (SWX:ARYN) has kicked off FY 2025 with first half revenue of €1.09b and basic EPS of €1.84, while trailing twelve month figures sit at €2.22b of revenue and EPS of €4.26, giving investors a clear view of the current earnings run rate. The company has seen revenue move from €1.06b and EPS of €1.65 in H1 FY 2024 to €1.14b and EPS of €2.40 in H2 FY 2024, with trailing twelve month net income reaching €112.3m. With a trailing net margin of 5.1% against 4.6% a year earlier, the latest...

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

Sandoz Group (SWX:SDZ) has received EU marketing authorization for Ranluspec. The approval expands the company’s biosimilars portfolio into the ophthalmology segment. The decision supports an expected product launch later in 2026 across European markets. For you as an investor, this represents a business development in a high-value area of medicine. Sandoz focuses on biosimilars and generics, and Ranluspec adds another product aimed at chronic eye conditions where long-term treatment is...

Sulzer (SWX:SUN) has drawn investor attention after reporting record 2025 EBITDA of CHF 556 million, record sales and order intake, and proposing a higher annual dividend of CHF 4.75 per share. See our latest analysis for Sulzer. Despite the strong 2025 results and higher dividend proposal, Sulzer’s recent share price has cooled, with a 1-day share price return decline of 1.53% and a 7-day share price return decline of 4.56%, while the 90-day share price return of 19.57% and 3-year total...

Siegfried Holding AG has reported past full-year 2025 results, with sales rising to CHF 1,327.83 million and net income to CHF 168.66 million, alongside higher basic and diluted earnings per share from continuing operations. At the same time, Siegfried is reshaping its operations by consolidating its Chief Operating Officer roles, as the COO for Drug Substances departs and an interim leader assumes expanded responsibilities. We’ll now examine how Siegfried’s higher full-year earnings and COO...

Why the infant formula recalls matter for Nestlé (SWX:NESN) Nestlé (SWX:NESN) is under close watch after recalling infant formula products in more than 60 countries due to low levels of the cereulide toxin, prompting tighter safety controls and raising fresh questions for shareholders about risk and resilience. See our latest analysis for Nestlé. Despite concerns around the recalls, Nestlé’s recent 30 day share price return of 13.32% and year to date share price return of 8.86% contrast with...

The latest earnings release from u-blox Holding (SWX:UBXN) put a sharp 54.43% FY 2024 revenue decline in focus, prompting investors to reassess margin pressure, liquidity strength, and R&D-heavy exposure to AI-enabled positioning markets. See our latest analysis for u-blox Holding. At a share price of CHF135.0, u-blox has seen strong momentum recently, with an 81.21% year to date share price return and a 108.01% total shareholder return over the past year. This suggests sentiment has shifted...

If you are wondering whether Roche Holding's current share price offers good value, you are not alone. This article will focus squarely on what investors may be paying for today. Roche's shares most recently closed at CHF 362.90, with a 2.0% decline over the last 7 days, a 3.5% gain over 30 days, 11.5% year to date, 23.9% over 1 year, 49.6% over 3 years and 41.3% over 5 years. Recent market attention on Roche has been driven by ongoing developments in its pharmaceuticals and diagnostics...

Recent commentary around rapid growth in digital mining, particularly for lithium and copper related to electric vehicles and the energy transition, has put ABB (SWX:ABBN) in focus as it expands partnerships and mining technologies. See our latest analysis for ABB. Against this backdrop of digital mining partnerships and technology deployments, ABB’s share price sits at CHF70.64, with a 90 day share price return of 22.98% and a 1 year total shareholder return of 47.76%. This suggests momentum...

Upcoming earnings put Comet Holding (SWX:COTN) under the AI spotlight Investor attention is building ahead of Comet Holding (SWX:COTN)'s 6 March 2026 earnings update, as the market looks for fresh clarity on AI linked semiconductor demand and order momentum in its Plasma Control Technologies division. See our latest analysis for Comet Holding. At a share price of CHF292.4, Comet is trading close to its 52 week high after a 90 day share price return of 38.71%, while the 1 year total...

Intershop Holding AG reported full-year 2025 results, with sales of CHF 86.54 million, revenue of CHF 119.11 million and net income of CHF 212.79 million, and announced an annual dividend of CHF 6.00 per share payable on April 8, 2026. The sharp increase in earnings per share from continuing operations to CHF 23.09 highlights how earnings growth is supporting Intershop Holding’s capacity to return cash to shareholders via a higher dividend. We’ll now examine how Intershop Holding’s strong...

Why Novartis is on investors’ radar today Novartis (SWX:NOVN) is in focus for investors after a strong run recently, with the share price showing double digit returns over the past month and the past 3 months. This performance is prompting closer attention to valuations. See our latest analysis for Novartis. Looking beyond the recent surge, Novartis’ share price is now at CHF130.5, with a 30 day share price return of 13.85% and a year to date share price return of 20.28%. The 1 year total...

Earnings trigger and why ARYZTA is back on investors’ radar ARYZTA (SWX:ARYN) has just reported its 2025 results, with revenue at €2.223b, a 1.5% increase, supported by free cash flow and cost saving efforts that include efficiency programs across the business. The company also announced plans to introduce a capital return policy in 2026 and highlighted an expectedly stronger balance sheet, developments that help explain why the stock is attracting fresh attention today. See our latest...

ams-OSRAM (SWX:AMS) is in the middle of a wide ranging shake-up, selling non optical sensor and specialty lamp businesses, cutting 2,000 jobs and pursuing sizeable cost savings to reshape its photonics and automotive focus. See our latest analysis for ams-OSRAM. These portfolio moves come after a period where the 90 day share price return of 20.46% contrasts with a 1 year total shareholder return of a 10.30% decline. This suggests some short term momentum while long term holders remain under...

dormakaba Holding (SWX:DOKA) moved into focus after its H1 2026 results, reporting sales of CHF 1,362.7 million and net income of CHF 40.5 million, both below the prior half year. See our latest analysis for dormakaba Holding. The H1 2026 earnings release helps explain why the 90 day share price return sits at a decline of 13.01%, even though the 3 year total shareholder return is a gain of 41.09% and recent momentum has weakened despite a 3.60% 1 day share price return to CHF57.5. If this...